AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1822804 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DF)
Number of subjects: 28
Study 6119779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0
Study 6119779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30787162 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined LDL-C
Number of subjects: 12389
Study 28187497 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy
Number of subjects: 88
Study 28187497 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy (compared to nonpregnant women)
Number of subjects: 88
Study 25892646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant with selumetinib
Number of subjects: 46
Study 25892646 — intervention group
Group type: COMPARATOR
Intervention: Placebo with fulvestrant
Number of subjects: 46
Study 23381882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 20 mg (phase 2)
Number of subjects: 8
Study 23381882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg (phase 3)
Number of subjects: 8
Study 23381882 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A4 probe)
Number of subjects: 8
Study 23381882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (p-glycoprotein probe)
Number of subjects: 8
Study 23381882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (OATP1B1 probe)
Number of subjects: 8
Study 21485941 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (written materials and a 2-hour education session)
Number of subjects: 100
Study 21485941 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 21485941 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 100
Study 19067190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with >= 5 ACF
Number of subjects: 52
Study 19067190 — intervention group
Group type: COMPARATOR
Intervention: Patients with < 5 ACF
Number of subjects: 52
Study 17309962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression (ISPC) device activated over the lower limbs 15 minutes after PPP was established for the remainder of surgery.
Number of subjects: 22
Study 17309962 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30) without ISPC during PPP.
Number of subjects: 22
Study 15312013 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer (WarmTouch 5700)
Number of subjects: 50
Study 15312013 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer (Bair Hugger 500)
Number of subjects: 50
Study 15312013 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater (Aragona Thermal Ceilings CTC X)
Number of subjects: 50
Study 15312013 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater (self assembled radiant heater of 4 Hydrosun 500 infrared lamps)
Number of subjects: 50
Study 15312013 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hospital blanket)
Number of subjects: 50
Study 11587671 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program
Number of subjects: 44
Study 11587671 — intervention group
Group type: COMPARATOR
Intervention: Control session (3 months after back school program)
Number of subjects: 44
Study 9869546 — intervention group
Group type: EXPERIMENTAL
Intervention: ABG monitor (SensiCath; Optical Sensors Inc.)
Number of subjects: 30
Study 9869546 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical laboratory analysis
Number of subjects: 30
Study 9869546 — intervention group
Group type: EXPERIMENTAL
Intervention: ABG monitor
Number of subjects: 30
Study 7978435 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered just before anesthesia
Number of subjects: 40
Study 7978435 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered 1 h before anesthesia
Number of subjects: 40
Study 7978435 — intervention group
Group type: COMPARATOR
Intervention: 250 micrograms triazolam orally 1 h before anesthesia (Group 1)
Number of subjects: 40
Study 7978435 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered 3 h before anesthesia
Number of subjects: 40
Study 2531606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine
Number of subjects: 7
Study 2531606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium
Number of subjects: 7
Study 1104900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 0
Study 1104900 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Number of subjects: 0
Study 1104900 — intervention group
Group type: COMPARATOR
Intervention: standard hormonal or other therapies
Number of subjects: 0
Study 31134822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU vitamin D3/day)
Number of subjects: 160
Study 31134822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 31743954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal OC2A and POCA (both within 95% CI of the healthy group)
Number of subjects: 30
Study 31743954 — intervention group
Group type: COMPARATOR
Intervention: Non-ideal OC2A and POCA (not within 95% CI of the healthy group)
Number of subjects: 30
Study 29084247 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion for 6 hours per day for up to 7 consecutive days
Number of subjects: 100
Study 29084247 — intervention group
Group type: COMPARATOR
Intervention: No hemoperfusion (control)
Number of subjects: 100
Study 25494405 — intervention group
Group type: EXPERIMENTAL
Intervention: A1166C polymorphism in the AT1 gene
Number of subjects: 250
Study 25494405 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 250
Study 23406306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling by phone, access to twice‐weekly exercise sessions, information on healthy eating and physical activity provided in pamphlets, evening meetings and an interactive website.
Number of subjects: 600
Study 23406306 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 600
Study 21726928 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (Group AGO)
Number of subjects: 183
Study 21726928 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (Group ANTAG)
Number of subjects: 183
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 rs1800779
Number of subjects: 18436
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 rs3918226
Number of subjects: 18436
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 rs1799983
Number of subjects: 18436
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE rs1799752
Number of subjects: 18436
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT rs699
Number of subjects: 18436
Study 18698212 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTR1 rs5186
Number of subjects: 18436
Study 16284192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 60
Study 16284192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12851342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (Synvisc)
Number of subjects: 100
Study 12851342 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone sodium phosphate‐betamethasone acetate, Celestone Soluspan)
Number of subjects: 100
Study 10383511 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose spearmint (500 mg)
Number of subjects: 0
Study 10383511 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavouring dose spearmint (0.5 mg)
Number of subjects: 0
Study 10383511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8723601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg in 15 min followed by 1 mg/kg in 2 h)
Number of subjects: 75
Study 8723601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1685992 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (40 mg bolus followed by an infusion of 18 mg.h‐1 for 2 h)
Number of subjects: 6
Study 1685992 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 6
Study 1685992 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil concentrations
Number of subjects: 6
Study 6809393 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine at a dose of 0.5 mg h‐1 kg‐1 given intravenously over 2 h
Number of subjects: 0
Study 6809393 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 0
Study 6809393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30259650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study 27662799 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized long-acting reversible contraception
Number of subjects: 916
Study 27662799 — intervention group
Group type: COMPARATOR
Intervention: Randomized short-acting reversible contraception
Number of subjects: 916
Study 27662799 — intervention group
Group type: COMPARATOR
Intervention: Preference short-acting reversible contraception
Number of subjects: 916
Study 27662799 — intervention group
Group type: EXPERIMENTAL
Intervention: Method continuers at 12 months (all groups)
Number of subjects: 916
Study 25778317 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiotherapy combined with concurrent combination chemotherapy (cisplatin and 5‐fluorouracil)
Number of subjects: 200
Study 25778317 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 200
Study 24131016 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous physical activity (MVPA)
Number of subjects: 240
Study 24131016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue interference (as an intermediate pathway)
Number of subjects: 240
Study 22390068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DN - 114001 (109 cells daily for 3 months)
Number of subjects: 0
Study 22390068 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation after 3 months)
Number of subjects: 0
Study 19641152 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) with tannic acid
Number of subjects: 976
Study 19641152 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) alone
Number of subjects: 976
Study 19641152 — intervention group
Group type: COMPARATOR
Intervention: No SDF application
Number of subjects: 976
Study 17692243 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold device
Number of subjects: 33
Study 17692243 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive load device
Number of subjects: 33
Study 17692243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 15458571 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicide intervention for contraception for 7 months
Number of subjects: 1514
Study 11248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic globo H‐keyhole limpet hemocyanin conjugates plus QS‐21 adjuvant
Number of subjects: 27
Study 12759987 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage in labour
Number of subjects: 0
Study 9298561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic workout or aerobic dance
Number of subjects: 63
Study 9298561 — intervention group
Group type: COMPARATOR
Intervention: Neutral video watching condition
Number of subjects: 63
Study 8097925 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol (200 mg)
Number of subjects: 12
Study 8097925 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol (mean 300 mg/day for 10 months)
Number of subjects: 12
Study 8097925 — intervention group
Group type: COMPARATOR
Intervention: Epanolol (300 mg/day)
Number of subjects: 12
Study 8097925 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (150 mg/day)
Number of subjects: 12
Study 3520318 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 626
Study 3520318 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 626
Study 3520318 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 626
Study 3520318 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (if needed)
Number of subjects: 626
Study 3520318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Hydrochlorothiazide (if needed)
Number of subjects: 626
Study 29149756 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 29149756 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study 29149756 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 129
Study 29149756 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 129
Study 29149756 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual anxiety (uncontrollable worry)
Number of subjects: 129
Study 27422403 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITCs)
Number of subjects: 605
Study 25069012 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of Variability (CV)
Number of subjects: 58
Study 25069012 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pumps
Number of subjects: 58
Study 22475362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding-avoidance strategies (BAS) including direct thrombin inhibitors and vascular closure devices
Number of subjects: 10469
Study 22475362 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors
Number of subjects: 10469
Study 22475362 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular closure devices
Number of subjects: 10469
Study 22475362 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 10469
Study 22475362 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk-adjusted bleeding
Number of subjects: 10469
Study 19821701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with an 830-nm diode laser, 40 mW, 1.04 J per point, applied on days 1, 3, 5, and 7 post-surgery
Number of subjects: 28
Study 19821701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 28
Study 18164458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extensor strengthening exercises
Number of subjects: 0
Study 15969244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (CR) 40 mg daily
Number of subjects: 64
Study 15969244 — intervention group
Group type: COMPARATOR
Intervention: Low-dose transdermal estradiol (TTSE2) 25 microg every 7 days plus dihydrogesterone 10 mg/day for the last 12 days
Number of subjects: 64
Study 14686229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0
Study 14686229 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 14686229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (oral)
Number of subjects: 0
Study 14686229 — intervention group
Group type: COMPARATOR
Intervention: CMV immune globulin i.v. and oral acyclovir
Number of subjects: 0
Study 10570746 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat IgG antiidiotype vaccine SCV 106 (n = 21)
Number of subjects: 42
Study 10570746 — intervention group
Group type: COMPARATOR
Intervention: Unspecific goat IgG (controls, n = 21)
Number of subjects: 42
Study 8966142 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and 1 alpha-OH-D3
Number of subjects: 75
Study 8966142 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 75
Study 8966142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-OH-D3 or 1.25(OH)2D3 alone
Number of subjects: 75
Study 8966142 — intervention group
Group type: COMPARATOR
Intervention: None of these drugs
Number of subjects: 75
Study 1679659 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 10
Study 1679659 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 10
Study 1679659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg
Number of subjects: 10
Study 1679659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1679659 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1 mg
Number of subjects: 10
Study 30078034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent workplace‐delivered intervention
Number of subjects: 231
Study 30078034 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 231
Study 26389719 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIT)
Number of subjects: 87
Study 26389719 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 87
Study 24874991 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training
Number of subjects: 63
Study 24874991 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 63
Study 23000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched side
Number of subjects: 15
Study 23000709 — intervention group
Group type: COMPARATOR
Intervention: Non-switched side
Number of subjects: 15
Study 23000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sides
Number of subjects: 15
Study 23000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal thickness
Number of subjects: 15
Study 20495473 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned placebo dose reduction condition (50% reduced dose/placebo)
Number of subjects: 99
Study 20495473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction only condition (RD)
Number of subjects: 99
Study 20495473 — intervention group
Group type: COMPARATOR
Intervention: No reduction condition (full dose)
Number of subjects: 99
Study 19086953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen (80 mg bolus followed by 8 mg/h continuous infusion for 72 h)
Number of subjects: 474
Study 19086953 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (40 mg bolus daily followed by saline infusion for 72 h)
Number of subjects: 474
Study 19086953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 474
Study 19086953 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 474
Study 19086953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 474
Study 16586078 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG whole-body PET scanning
Number of subjects: 33
Study 14752969 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM) putty delivery system
Number of subjects: 10
Study 11055317 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation
Number of subjects: 0
Study 11055317 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation combined with early stimulation programme
Number of subjects: 0
Study 11055317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse counselling once a week for 6-8 weeks
Number of subjects: 0
Study 8922050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp protocol
Number of subjects: 20
Study 8922050 — intervention group
Group type: COMPARATOR
Intervention: Incremental protocol
Number of subjects: 20
Study 1526689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 6
Study 1526689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12267108 — intervention group
Group type: EXPERIMENTAL
Intervention: ML Cu250
Number of subjects: 1725
Study 12267108 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu-220C
Number of subjects: 1725
Study 12267108 — intervention group
Group type: COMPARATOR
Intervention: Cu7
Number of subjects: 1725
Study 12267108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation rates at 24 months: Cu7 (69), TCu-220C (73), ML Cu250 (74).
Number of subjects: 1725
Study 31396621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interventions (IPC, CM, MM)
Number of subjects: 2000
Study 31396621 — intervention group
Group type: COMPARATOR
Intervention: Nonintensive interventions (standard IPC, less‐intensive CM and MM)
Number of subjects: 2000
Study 30412626 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (ACT)
Number of subjects: 46
Study 30412626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 46
Study 30412626 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (MAS)
Number of subjects: 46
Study 30412626 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 46
Study 27454509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon interposition arthroplasty
Number of subjects: 120
Study 27454509 — intervention group
Group type: COMPARATOR
Intervention: K. wire distraction
Number of subjects: 120
Study 24119718 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative alfacalcidol supplementation (group B)
Number of subjects: 219
Study 24119718 — intervention group
Group type: COMPARATOR
Intervention: No alfacalcidol supplementation (group A)
Number of subjects: 219
Study 22336776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate 100 mg
Number of subjects: 16
Study 22336776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate 200 mg
Number of subjects: 16
Study 22336776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate 400 mg
Number of subjects: 16
Study 22336776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate 400 mg plus antibacterial toothpaste
Number of subjects: 16
Study 22336776 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Nitrate (Control)
Number of subjects: 16
Study 22336776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate doses (100 mg, 200 mg, 400 mg)
Number of subjects: 16
Study 22336776 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial toothpaste
Number of subjects: 16